SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of...
Read More Details
Finally We wish PressBee provided you with enough information of ( Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC )
Also on site :
- Legendary Hard Rock Band Racks Up the Heavy Metal as Iconic Album Hits Sales of 20 Million
- 7UP Confirms Return of Limited-Edition Flavor That Once Flew Off Shelves
- 'Days of Our Lives' Alum Has Fans 'Crying' Over Photo During 'Last Father Daughter Dance'